Cipla Shares to Trade Ex-Date on June 27: How Much Dividend Income Will 1,000 Shares Earn?

On June 27, 2025, Cipla shares will trade ex-date, meaning that the shareholders registered in the company’s books will be eligible for the ₹13 final dividend and ₹3 special dividend.

Cipla said in an exchange filing, “The Board of Directors of the Company also recommended a final dividend of INR 13/- per equity share for the financial year ended 31st March, 2025 and a special dividend of INR 3/- per equity share on the occasion of completing 90 years of the Company, taking the total dividend to INR 16/- per equity share (face value INR 2 each). The dividend, upon approval by the shareholders, will be paid to shareholders within 30 days from the date of the Annual General Meeting. The record date for the purpose of payment of final dividend, if declared, shall be 27th June 2025.”

How Much Dividend Will You Get With 1,000 Shares?

• Final Dividend: ₹13 per share
• Special Dividend: ₹3 per share
• Total Dividend: ₹16 per share
• Face Value of Each Share: ₹2 (for information; this doesn't affect dividend amount directly)
• Number of Shares Owned: 1,000 shares

Cipla 2025 Dividend Calculation

Total Dividend=Number of Shares × Dividend per Share

Total Dividend=1,000×₹16=₹16,000

As per the calculations, you will receive a total dividend of ₹16,000 if you own 1,000 shares on the record date, i.e., June 27, 2025, subject to approval of shareholder at the AGM.

Who is Eligible for Cipla Dividend?

To be eligible for Cipla’s final dividend of ₹16 per share, you needed to be a registered shareholder as of the record date—June 27, 2025. However, due to India’s T+1 (Trade plus One day) settlement system, only investors who bought the shares on or before June 26, 2025, will qualify. Under T+1 settlement, shares purchased on a given day are officially credited to your demat account on the next trading day.

Cipla Dividend History

Also Read: Bonus, Stock Split and Dividend This Week June 23-27: HUL, Samvardhana Motherson, Bajaj Holdings and More

Cipla Management Take on Q4FY25 Earnings

Umang Vohra, MD and Global CEO, Cipla Ltd, said, “I am pleased to share that we continue to make considerable progress across our focused markets. In FY25, we recorded a revenue growth of 8% over last year with the EBITDA margin of 25.9%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 7% YoY. Key therapies in the Branded Prescription business continued to outpace the market growth, the Trade Generics business growth trajectory is back on track, and the Anchor brands of the Consumer Health Business maintained a leadership position. “

He further added, “With a positive traction in our differentiated assets, the US business posted an all-time high annual revenue of $ 934 Mn. In One Africa, we recorded a solid growth of 12% YoY in USD terms, powered by firm performance across key markets. Emerging Markets and Europe delivered a substantial revenue growth of 15% YoY on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipeline, as well as focusing on resolutions on the regulatory front”.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.